Business Services
Pharmaceutical Business Services – News, analysis and company profiles
Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023
April 18, 2023 Business Services
BASEL, Switzerland – 18th April 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, …
MED3000, Eroxon® UK Launch
April 18, 2023 Business Services
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on …
Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Association for Cancer Research Annual Meeting
April 18, 2023 Business Services
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it …
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
April 18, 2023 Business Services
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces …
We need more “trial” and less error – a concerted effort is required to include more people aged over 60 in clinical trials, argues longevity experts
April 18, 2023 Business Services
The Trial and error report, published today, urges regulators, pharmaceutical companies and researchers to prioritise age diversity at all stages …
Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer
April 17, 2023 Business Services
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented updated interim clinical efficacy data including subgroup analyses of first-line pancreatic cancer …
ClinOne Closes Series A Funding Round to Scale its Site and Participant Engagement Platform, Data Driven Insights and Interoperability
April 17, 2023 Business Services
BOSTON AND BOULDER, COLO. (PRWEB) APRIL 13, 2023 – ClinOne, the leading provider of Adaptive Experiences in clinical trials announced …
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favourable Tolerability and Immunogenicity Profile
April 17, 2023 Business Services
OXFORD, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) – Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …
ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens
April 17, 2023 Business Services
OSAKA, Japan, APRIL 17, 2023 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; …
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
April 17, 2023 Business Services
CAMBRIDGE, MA, April 17, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based …
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
April 17, 2023 Business Services
BOSTON and WILMINGTON, Del. – April 16, 2023 – MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: …
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
April 17, 2023 Business Services
Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group …
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
April 14, 2023 Business Services
NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical …
UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal
April 13, 2023 Business Services
Brussels (Belgium) 13 April 2023 – 07:00 AM (CET) – UCB, a global biopharmaceutical company, today announced that The Lancet Neurology …
Adaptyv Bio creates a new paradigm for protein engineering using generative AI, open-source software and synthetic biology
April 13, 2023 Business Services
Lausanne, Switzerland – 13th April 2023; AI tools like ChatGPT are revolutionizing how the world generates text, images and code. …
Latest content
Pharma sees climate disruption as growing supply-chain risk
September 11, 2026
Manchester NHS-MHRA partnership to test new technologies in real-world care
September 10, 2026
